Shearman & Sterling represented the joint book-running managers and representatives of the underwriters in connection with Amgen’s registered $5 billion notes offering, consisting of 1.650 percent senior notes due 2028, 2.000 percent senior notes due 2032, 2.800 percent of senior notes due 2041 and 3.000 percent senior notes due 2052. Amgen is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics based on advances in cellular and molecular biology.

The Team